Gain Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell GANX and other ETFs, options, and stocks.

About GANX

Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never targeted before. Its See-Tx target identification platform uses the published 3D structure of enzymes and a proprietary computational technology to discover new allosteric binding sites and predict their druggability. 

CEO
Gene C. Mack
CEOGene C. Mack
Employees
25
Employees25
Headquarters
Bethesda, Maryland
HeadquartersBethesda, Maryland
Founded
2017
Founded2017
Employees
25
Employees25

GANX Key Statistics

Market cap
70.58M
Market cap70.58M
Price-Earnings ratio
-2.83
Price-Earnings ratio-2.83
Dividend yield
Dividend yield
Average volume
1.50M
Average volume1.50M
High today
$1.98
High today$1.98
Low today
$1.77
Low today$1.77
Open price
$1.95
Open price$1.95
Volume
1.85M
Volume1.85M
52 Week high
$4.34
52 Week high$4.34
52 Week low
$1.41
52 Week low$1.41

Stock Snapshot

With a market cap of 70.58M, Gain Therapeutics(GANX) trades at $1.85. The stock has a price-to-earnings ratio of -2.83.

On 2026-01-17, Gain Therapeutics(GANX) stock traded between a low of $1.77 and a high of $1.98. Shares are currently priced at $1.85, which is +4.5% above the low and -6.6% below the high.

Gain Therapeutics(GANX) shares are trading with a volume of 1.85M, against a daily average of 1.5M.

During the past year, Gain Therapeutics(GANX) stock moved between $1.41 at its lowest and $4.34 at its peak.

During the past year, Gain Therapeutics(GANX) stock moved between $1.41 at its lowest and $4.34 at its peak.

People also own

Based on the portfolios of people who own GANX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .